Tecon Biology's subsidiary application for Beijing exchange listing accepted

Tecon Biology (SZSE:002100) announced that its controlling subsidiary, Tecon Pharmaceutical, a company listed on the National Equities Exchange and Quotations (NEEQ: 874339), has had its application accepted for a public offering of shares and subsequent listing on the Beijing Stock Exchange. Tecon Pharmaceutical submitted the relevant application materials to the Beijing Stock Exchange on June 20, 2025, and received the official acceptance notice (GF2025060019) on June 23, 2025. While the application has been accepted, Tecon Biology cautions investors that the listing is subject to the approval of the Beijing Stock Exchange and the China Securities Regulatory Commission, and there remains a risk that the offering may not be successful. The company will continue to disclose relevant information in accordance with applicable laws and regulations.